Analyst Ratings For AMAG Pharmaceuticals (NASDAQ:AMAG)
Today, AMAG Pharmaceuticals (NASDAQ:AMAG) stock received an upgrade by Janney Montgomery Scott from Neutral to Buy with a price target of $45.00.
Some recent analyst ratings include
- 2/15/2018-Janney Montgomery Scott Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 2/14/2018-Cantor Fitzgerald Reiterated Rating of Hold.
- 2/2/2018-Leerink Swann Reiterated Rating of Market Perform.
- 1/29/2018-B. Riley Reiterated Rating of Hold.
- 1/18/2018-Piper Jaffray Companies Reiterated Rating of Hold.
- 11/5/2017-Jefferies Group Reiterated Rating of Buy.
- On 8/29/2017 Joseph Vittiglio, SVP, sold 1,250 with an average share price of $16.75 per share and the total transaction amounting to $20,937.50.
- On 7/13/2017 Julie Krop, SVP, sold 4,938 with an average share price of $20.00 per share and the total transaction amounting to $98,760.00.
- On 5/1/2017 Julie Krop, SVP, sold 1,891 with an average share price of $24.45 per share and the total transaction amounting to $46,234.95.
- On 10/20/2016 Julie Krop, SVP, sold 4,938 with an average share price of $24.80 per share and the total transaction amounting to $122,462.40.
- On 11/10/2015 John A Fallon, Director, bought 3,230 with an average share price of $31.20 per share and the total transaction amounting to $100,776.00.
- On 10/1/2015 William K Heiden, CEO, sold 2,000 with an average share price of $39.69 per share and the total transaction amounting to $79,380.00.
- On 9/1/2015 William K Heiden, CEO, sold 2,000 with an average share price of $61.19 per share and the total transaction amounting to $122,380.00.
Recent Trading Activity for AMAG Pharmaceuticals (NASDAQ:AMAG)
Shares of AMAG Pharmaceuticals closed the previous trading session at 16.85 up +2.95 21.22% with 17.0 shares trading hands.